HARTREE-PARTNERS
7.3.2024 08:01:28 CET | Business Wire | Press release
Hartree Partners (UK) Limited (“Hartree”), a wholly owned subsidiary of Hartree Partners LP, which is co-owned by its partners and funds managed by Oaktree Capital Management, announced that it has signed an acquisition agreement for a 50% share in Botres Holding GmbH and its subsidiaries (“Botres”). Headquartered in Graz, Austria, Botres is a key supplier of ultra-modern industrial biogas plants and biorefineries in Austria, Czech Republic, Poland, Italy, Spain and Turkey. Through Bio Scraper, its highly efficient biowaste treatment system, Botres covers the entire processing chain from pre-treatment of all types of organic waste to the efficient production of green energy.
Since being founded in 2012, Botres has built numerous biogas plants across Europe and Turkey and serves some of the world’s largest waste management and infrastructure companies. Botres is led by its founders Dr. Stefan Kromus and Dr. Markus Grasmug, who serve as Managing Directors. Jointly, Dr. Kromus and Dr. Grasmug have over 40 years of experience in the design, development, construction, and operation of waste focused biomethane plants.
Hartree is partnering with Botres to develop a European biomethane production business with a focus on Renewable Energy Directive (RED) compliant feedstocks, which will operate under the Botres brand. The business will focus asset development activities in select countries within the EU and will expand into additional countries on an opportunity-led basis.
“We are excited to partner with Botres, whose innovative technology and proven track record in the biogas space make them an excellent partner for our team as we enter the European biomethane production market. This collaboration directly aligns with Hartree's transition to investing in renewable energy solutions and we look forward to playing a role in providing Europe with clean and reliable biomethane,” said Stephen Hendel, Founding Managing Partner of Hartree Partners LP.
Dr. Kromus said, “We are thrilled to embark on this new chapter with Hartree Partners. This partnership presents a significant opportunity to accelerate the growth of our biomethane production business and solidify Botres' position as a leading player in the industry. We are confident that by combining our expertise and resources, we can deliver exceptional results for our stakeholders and contribute meaningfully to Europe's transition towards a more sustainable energy future.”
About Hartree:
Hartree Partners (UK) Limited is a wholly owned subsidiary of Hartree Partners, LP a limited partnership organised under the laws of Delaware and is a global commodities firm actively trading in oil, gas, power, refined products, shipping, metals and equities. Hartree Partners, LP was established more than 25 years ago and is jointly owned by senior management and funds managed by Oaktree.
Hartree has a unique 25+ year track record in proprietary trading and investing in energy markets across the globe. Our asset development experience ranges from VLCCs, oil, gas and power storage, power generation (conventional & renewable), and gas production facilities, as well as oil refining assets in the US. In Europe Hartree is involved in the UK power market through a portfolio of peak power assets, as well as a portfolio of pan-European renewable generation assets. Hartree acquired a deep knowledge base in the operation of these assets through extensive data analytics and has a wealth of experience in structuring transactions for renewable power and managing intermittent load.
About Botres:
Botres Holding/Botres Global GmbH, headquartered in Graz, Austria, is a leading supplier of modern industrial-scale anaerobic digestion biogas technology, covering the entire process chain from pre-treatment of all types of organic waste, manure and other residues to the efficient production of green energy. Botres was founded in 2012 and emerged from technology development at one of the world’s largest and most successful anaerobic digestion plants in Italy.
Over the past years, Botres has built numerous biogas plants in various European countries, Turkey and Australia. Among Botres’ customers are some of the largest waste management and infrastructure companies in the world. With the development of its highly efficient biowaste treatment system (Bio Scraper), Botres is able to treat basically any type of organic waste. In addition, the technological design and process stability of the plants ensure optimized life cycle expenditures.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306806400/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom